Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
... is characterized by Wyeth as a TSEC (tissue
selective estrogen complex) as it combines a
selective estrogen receptor modulator (SERM) with ... Protection in Menopausal Therapy with a Tissue
selective Estrogen Complex (TSEC) Containing ...
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
... we show that plant-derived ERb compounds are as
selective as synthetic compounds, but regulate different ... the analyses of three distinct classes of ERb
selective drugs. The study determines the relative ER ... of gene expression of the three classes of ERb
selective compounds compared to the natural hormone ...
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
... published today in Nature Medicine, Proteolix's
selective immunoproteasome inhibitor PR-957 was shown to ... July 2009 print edition in an article titled: A
selective Inhibitor of the Immunoproteasome Subunit LMP7 ... Chief Scientific Officer at Proteolix. "This
selective inhibition of the immunoproteasome results in an ...
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
... demonstrated promising activity as a highly
selective and potent inhibitor of the proteasome for ... A Phase Ib/II study of carfilzomib (CFZ), a
selective proteasome inhibitor, in patients with selected ... a selective, oral proteasome inhibitor and a
selective immunoproteasome inhibitor. For additional ...
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
... on INTUNIV (guanfacine) extended release, a
selective alpha-2A-agonist, at a major psychiatric meeting. ... Once available, INTUNIV will be the first
selective alpha-2A receptor agonist approved for the ... understood, preclinical research suggests this
selective alpha-2A agonist strengthens working memory and ...
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
... -- RAPAFLO (TM) (silodosin), a new, uniquely
selective alpha blocker for the treatment of the signs and ... reduced semen), an expected treatment effect of
selective alpha blockers, which occurred in 28 percent of ...
RAPAFLO(TM) is an effective, uniquely
selective alpha-1 adrenergic receptor antagonist. ...
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
... placebo. Varespladib is a potent and highly
selective oral inhibitor of secretory phospholipase A2 ... cholesterol
- Varespladib's immediate and
selective inhibition of sPLA2 effectively suppressed ... clinical trials, varespladib, a potent and highly
selective inhibitor of secretory phospholipase A2 (sPLA2), ...
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
... molecular target. CX-4945 is a potent,
selective inhibitor of CK2 and modulates key survival ... PM Discovery and characterization of CX-4945 a
selective orally bioavailable small molecule inhibitor of ... April 21, 2009: 2:00 PM CX -4945, a potent and
selective inhibitor of CK2, modulates PI3K/AKT signaling ...
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
... First
selective TLR8 Agonist to Advance for Treatment of Allergy ... initiated a Phase I clinical trial of VTX-1463, a
selective intranasal TLR8 agonist for the treatment of ... later this year.
"VTX-1463 is the first
selective TLR8 compound to reach the clinic for allergy," ...
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
... tolerability of PCI-32765,
an orally available,
selective inhibitor of Bruton's tyrosine kinase, or Btk,
as ... lymphoma (NHL). This is the first Btk
selective inhibitor to
be tested in humans, and is ... for the patient.
"This is a very
selective compound for B-cells, and it could represent ...
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
... (TM) (silodosin), the company's new, uniquely
selective alpha blocker for the treatment of the signs and ... About RAPAFLO
RAPAFLO(TM) is an effective,
selective alpha-1 adrenergic receptor antagonist that binds ... with reduced semen), an expected effect of
selective alpha blockers. Rates of discontinuing therapy ...
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
... Phase 3 clinical trial for Ophena(TM) , a novel
selective estrogen receptor modulator (SERM) for the ... preclinical program. Fispemifene is a new
selective estrogen receptor antagonist that is in Phase 2 ... and other conditions in men. Sobetirome, a novel,
selective thyroid receptor beta agonist, is in Phase 1 as a ...
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
... First
selective TLR8 Agonist to Advance to Clinical Trials
... initiated a Phase I clinical trial of VTX-2337, a
selective TLR8 agonist for the treatment of cancer. The ... stage cancer.
"VTX-2337 is the first
selective TLR8 compound to reach the clinic and we are ...
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
... Excluding
Therapy Poster II
-- The
selective Proteasome Inhibitor Carfilzomib is Well ... -- Induction of Sustained Early G1 Arrest by
selective Inhibition of
CDK4 and CDK6 Primes ... including an oral
proteasome inhibitor and a
selective immunoproteasome inhibitor. For
additional ...
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
... were presented at
EORTC.
-- MLN8237, an oral
selective Aurora A kinase inhibitor: initial results of ... (PK), and pharmacodynamics (PD) of MLN8237, a
selective Aurora A kinase inhibitor, in the United ... TAK-593
TAK-593 is a novel small molecule
selective inhibitor of the tyrosine
kinases for the VEGF ...
Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
... on the company's
second estrogen receptor beta
selective drug candidate that will be
entering clinical ... explain the safety
advantages of this more highly
selective estrogen receptor modulator,
VG101, when compared ... women. VG101 is a novel estrogen receptor
beta
selective agonist and unlike currently available hormone ...
Novel Compound Shows Promise for Treatment of Alcoholism
... and suggests that a new compound that
causes
selective and long-lasting reduction in ethanol consumption ... Opioid Receptor Antagonist, SoRI-9409,
Produces a
selective and Long-Lasting Decrease in Ethanol Consumption ... results demonstrate that this compound causes
selective and
long-lasting reductions of ethanol ...
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
... MF101, an estrogen receptor beta
selective modulator, regulated
calcium levels, which are ... estrogen receptor beta. MF101 demonstrated
this
selective regulation."
The study was conducted by ... MF101
MF101 is an estrogen receptor beta (ER-b)
selective drug for the
treatment of menopausal hot flashes, ...
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
... analyses of pivotal trial
results of INTUNIV, a
selective alpha-2A-agonist. This compound is ... label. Upon approval,
INTUNIV will be the first
selective alpha-2A receptor agonist indicated for
the ... and frustration tolerance. The
selective alpha-2A agonist
strengthens working memory and ...
Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
... histone deacetylase
(HDAC) inhibitor and HDAC-8
selective inhibitor were presented.
"These presentations ... models.
"We believe that PCI-34051 is a truly
selective HDAC-8 inhibitor," said
Sriram Balasubramanian, ... cells.
Scientists have been searching for more
selective inhibitors, which may
offer the potential for ...
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
...
selective Kinase Inhibitor Phase 1 Trial in Advanced Cancer ... )
ENMD-2076 is a novel,
selective kinase inhibitor with potent activity
against ... Officer commented,
"ENMD-2076 is an exciting
selective kinase inhibitor with potent single
agent ...
FASgen Announces a New Discovery in Obesity Research
... FASgen is a leader in
the field of research into
selective inhibition of fatty acid synthase
(FASi), and has ... (CPT-1). FAS89B was characterized in vitro
as a
selective inhibitor of brain CPT-1 and produced in vivo ... to create new
therapeutic products based on the
selective inhibition of fatty acid
biosynthesis. The ...
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
... discovered, oral, potent, and highly
selective JAK2 inhibitor in
January, 2008. Additionally, ... presentations include:
-- Catriona Jamieson --
selective Inhibition of JAK2 Driven Erythroid ... Cell Experiments with TG101348, A JAK2
selective Small Molecule Inhibitor, in the Presence of ...
New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
... at Anti-Angiogenesis Conference Shows R84, the
selective Human Anti-VEGF Antibody Developed by Peregrine ... to both VEGFR2 and VEGF receptor 1 (VEGFR1).
selective anti-VEGF
agents may have potential advantages ... The data we previously
presented on 2C3, our
selective anti-VEGF mouse antibody, along with the
current ...
Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
... preclinical data shows that MSI-1436
demonstrated
selective inhibition of PTP-1B but did not inhibit ... The study confirmed that MSI-1436 is a
selective inhibitor of PTP-1B,
and its central and ... that trodusquemine is a potent, highly
selective and reversible
inhibitor of PTP-1B. In vitro ...
New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
... PI3K pathway signaling with XL147, a potent,
selective and orally bioavailable PI3K inhibitor (Abstract ... -- Biomarker development for XL765, a potent and
selective oral dual inhibitor of PI3K and mTOR ... (PK) study of XL647, a novel spectrum
selective kinase inhibitor, administered orally daily to ...
Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
... - RDEA119: A Potent and
selective MEK inhibitor with Favorable In Vitro and ... abstract entitled
"RDEA119: A Potent and Highly
selective MEK Inhibitor for the Treatment of
Cancer," will ... Title: RDEA119: A Potent and Highly
selective MEK Inhibitor for the Treatment of ...
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
... Women to Evaluate QuatRx's New-Generation
selective Estrogen Receptor Modulator (SERM)
ANN ARBOR, ... with menopause. Ophena(TM) is a new-generation
selective estrogen receptor modulator
(SERM) for ... development programs. Fispemifene is a new,
selective estrogen
receptor antagonist that is in Phase 2 ...
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
... Shire Specialty Pharmaceuticals. "When approved,
INTUNIV will be the first
selective alpha-2A receptor agonist for the
treatment of ADHD, and will provide ... of ADHD is
not fully understood, preclinical research suggests this
selective alpha-2A
agonist strengthens working memory and prefrontal cortex neuronal ...
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
... Krenitsky Pharmaceuticals Inc., which also licensed the RIMA series of
selective and reversible monoamine oxidase inhibitor (MAOI) compounds to CeNeRx. ... a series of novel compounds for anxiety and depression; and a series of
selective cannabinoid compounds that have recently completed successful preclinical ...
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
... study indicate that paclitaxel poliglumex may be a uniquely active and
selective radiosensitizing therapeutic. Most importantly, patient tolerability ... of severe gastrointestinal toxicity. It is likely that this is due to the
selective accumulation of paclitaxel poliglumex in tumor tissue with continual slow ...
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
...
"In spite of advances in the treatment of multiple myeloma, new
selective agents are needed for patients who have failed other available therapies," ... inhibitors, including a selective, oral proteasome inhibitor and a
selective immunoproteasome inhibitor. For additional information on Proteolix, ...
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
... company's proof-of-concept Phase 2a study of RAD1901, an investigational
selective estrogen receptor modulator (SERM) undergoing clinical evaluation for ... effect--will be collected.
About RAD1901
RAD1901 is a novel
selective estrogen receptor modulator (SERM) under development at Radius as a new ...
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
... enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD
selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes ... initiation of the INT131 Phase 3 program in 1H2010."
INT131 is a
selective PPAR gamma modulator which has consistently demonstrated the separation of ...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
... 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly
selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of ...
About Trodusquemine (MSI-1436)
Trodusquemine is the first highly
selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to ...
Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
... selectively. This provides an excellent insight into Angiolix's tumor
selective mechanism. Angiolix(R) is a promising novel agent for anti-angiogenic ... in treating cancer, there is clearly a need to bring a more tumor
selective product like Angiolix to the market," stated Jeffrey B. Davis, President ...
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
... orally administered small molecule anticancer agent that delivers highly
selective and potent inhibition of CK2, a constitutively active protein kinase that ... it has an unusual active site. CX-4945 represents the first potent and
selective inhibitor of CK2 with a favorable safety profile and the ability to ...
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
... peripherally to regulate insulin and leptin pathways through the highly
selective inhibition of its novel target enzyme, PTP-1B.
Study 102 will ... and peripherally-acting appetite suppressant and the first highly
selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... receiving placebo;
BRIDION(R) (sugammadex), the first and only
selective relaxant binding agent for reversing neuromuscular blockade in anesthesia ... that MFF met its primary endpoints; and
Preladenant, a novel and
selective adenosine2a receptor antagonist for Parkinson's disease (completing Phase ...
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
... Corporation (NYSE: SGP ) today reported that preladenant, its novel and
selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II ... treatment options. Its pharmacological profile as both a potent and
selective adenosine type 2a receptor antagonist has previously been shown to have ...